Year archive

Isofol Medical — 2026 filings

All 24 regulatory filings released by Isofol Medical (ISOFOL) in 2026, sourced directly from the official regulator.

24 Filings

2026 Period

2026 filings (24)

Filing	Released	Lang
Major Shareholding Notification 2026 Major Shareholding Notification	2026-05-22	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-05-21	English
Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 Declaration of Voting Results & Voting Rights Announcements	2026-05-19	English
Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2026 Declaration of Voting Results & Voting Rights Announcements	2026-05-19	Swedish
Nytt antal aktier och röster i Isofol Regulatory Filings	2026-04-30	Swedish
New number of shares and votes in Isofol Regulatory Filings	2026-04-30	English
Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ) AGM Information	2026-04-15	English
Kallelse till årsstämma den 19 maj 2026 i Isofol Medical AB (publ) AGM Information	2026-04-15	Swedish
Major Shareholding Notification 2026 Major Shareholding Notification	2026-04-10	Swedish
Annual Report 2025 Annual Report FY 2025	2026-04-10	Swedish
Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue Share Issue/Capital Change	2026-03-31	English
Isofol erhåller bruttolikvid om 18,9 MSEK i samband med optionsinlösen och garantiåtagande för teckningsoptioner av serie TO1 samt beslutar om riktad nyemission Share Issue/Capital Change	2026-03-31	Swedish
Isofols säkrar licensrättigheter för arfolitixorin inom autism Regulatory Filings	2026-03-18	Swedish
Isofol secures license rights for arfolitixorin in autism Regulatory Filings	2026-03-18	English
Teckningskursen för teckningsoptioner av serie TO1 i Isofol har fastställts till 0,48 SEK och nyttjandeperioden inleds den 16 mars 2026 Share Issue/Capital Change	2026-03-13	Swedish
The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026 Share Issue/Capital Change	2026-03-13	English
Isofol erhåller toppgarantiåtagande och avsiktsförklaringar motsvarande 42 procent av kommande optionsinlösen Capital/Financing Update	2026-03-11	Swedish
Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise Capital/Financing Update	2026-03-11	English
Isofols valberedning föreslår nyval av Christian Haglund Board/Management Information	2026-03-09	Swedish
Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director Board/Management Information	2026-03-09	English
Isofol lämnar uppdatering från pågående klinisk fas Ib/II-studie av arfolitixorin Regulatory Filings	2026-02-24	Swedish
Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin Regulatory Filings	2026-02-24	English
Interim / Quarterly Report 2025 Interim / Quarterly Report Q4 2025	2026-02-18	Swedish
Interim / Quarterly Report 2025 Interim / Quarterly Report Q4 2025	2026-02-18	English